Marshall Wace
PACB icon

Marshall Wace’s Pacific Biosciences PACB Stock Holding History

Marshall Wace’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$275K Buy
163,642
+82,342
+101% +$120K ﹤0.01% 2756
2026
Q1 		$107K Buy
+81,300
New +$145K ﹤0.01% 2886
2025
Q1 		– Sell
-50,900
Closed -$93.1K – 2971
2024
Q4 		$93.1K Sell
50,900
-2,071,020
-98% -$4.04M ﹤0.01% 2449
2024
Q3 		$3.61M Buy
2,121,920
+510,620
+32% +$839K ﹤0.01% 1124
2024
Q2 		$2.21M Buy
1,611,300
+1,117,966
+227% +$2.26M ﹤0.01% 1315
2024
Q1 		$1.85M Buy
493,334
+349,246
+242% +$2.04M ﹤0.01% 1400
2023
Q4 		$1.41M Sell
144,088
-344,380
-71% -$2.82M ﹤0.01% 1360
2023
Q3 		$4.08M Buy
+488,468
New +$5.58M 0.01% 948
2023
Q2 		– Sell
-11,500
Closed -$133K – 2840
2023
Q1 		$133K Sell
11,500
-63,600
-85% -$632K ﹤0.01% 2461
2022
Q4 		$614K Sell
75,100
-14,500
-16% -$125K ﹤0.01% 2298
2022
Q3 		$520K Buy
+89,600
New +$514K ﹤0.01% 2710
2020
Q4 		– Sell
-146,005
Closed -$1.44M – 2099
2020
Q3 		$1.44M Sell
146,005
-2,256
-2% -$13K 0.01% 897
2020
Q2 		$512K Sell
148,261
-38,356
-21% -$131K ﹤0.01% 1193
2020
Q1 		$571K Sell
186,617
-101,027
-35% -$414K 0.01% 948
2019
Q4 		$1.48M Sell
287,644
-380,493
-57% -$1.93M 0.01% 891
2019
Q3 		$3.45M Buy
668,137
+396,180
+146% +$2.22M 0.03% 604
2019
Q2 		$1.65M Sell
271,957
-685,257
-72% -$4.81M 0.01% 822
2019
Q1 		$6.92M Buy
957,214
+337,213
+54% +$2.44M 0.07% 366
2018
Q4 		$4.59M Buy
+620,001
New +$3.93M 0.05% 466

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace's PACB Position: Q2 2026 in Review

Marshall Wace increased its Pacific Biosciences (PACB) stake by 101% in Q2 2026, buying an estimated $120K and bringing the position to 163,642 shares worth $275K. The position accounts for ﹤0.01% of the portfolio, ranked #2756.

Marshall Wace first reported a position in PACB in Q4 2018 and has held it in 19 quarters since. The position peaked at $6.92M in Q1 2019. 222 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Marshall Wace held 163,642 shares of Pacific Biosciences worth $275K as of Q2 2026.
  • Marshall Wace bought 82,342 Pacific Biosciences shares in Q2 2026, an estimated $120K.
  • Pacific Biosciences made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2756 holding.
  • Marshall Wace first reported a position in Pacific Biosciences in Q4 2018 and has held it in 19 quarters since.
  • Marshall Wace's Pacific Biosciences position peaked at $6.92M in Q1 2019.
  • 222 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.